How to make your money go further

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · AstraZeneca (AZN)  · GlaxoSmithKline (GSK) 

Dividends FTSE 100 Shares

Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been to focus on bulking up its pipeline with exciting, novel therapies. It's very different to the 'steady as she goes' approach employed by GlaxoSmithKline which, though underwhelming, might be better for income seekers.

Sign up and read the full Blog

Register to continue reading this article.

Get FREE access now

Already a member? Login

Have your say

Log in or register to view or add comments.

Get free access now

Register free to gain access to more research

Register

Investor's Champion Premium Company Research

Subscribers to our Premium Company Research receive priority notification by email of newly published research. Premium company research costs as little as £3.20 per research note.

More on Premium Research

More on AstraZeneca

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More on GlaxoSmithKline

Astra vs GSK. Drugs vs Dividends.

16/11/2018 · Blog
Update: AstraZeneca has failed another drugs trial. That's the risk of its strategy which has been…

More from the Blog

Fibre Wars: How long will BT hold onto its crown?

21/11/2018 · BT · TalkTalk · Vodafone

FAANG bear market: Fear or fake?

20/11/2018 · Alphabet · Amazon · Apple · Facebook · Netflix

Johnston Press: A warning to media investors

19/11/2018 · Reach